SCHEMBL4580975

SCHEMBL4580975

O=C1NCCN(c2ccnc(Nc3ccc(Cl)cc3)n2)C1c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
SCN9A Q15858 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
ALK Q9UM73 1/20 0.39
SMG1 Q96Q15 1/20 0.38
KDR P35968 6/20 0.38
AKT1 P31749 1/20 0.38
PTK2 Q05397 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
PLK1 P53350 1/20 0.38
EIF2AK2 P19525 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4582376 0.93 KDR (0.43) IKBKBCHUKALKSMG1KDR
SCHEMBL4580865 0.90 MAPK14 (0.42) GSK3AGSK3BKDRMKNK1EIF2AK2
SCHEMBL4580811 0.89 KDR (0.51) ALKSMG1KDREIF2AK2GRM5
SCHEMBL4581955 0.88 IKBKB (0.42) IKBKBCHUKSCN9AGSK3AGSK3B
SCHEMBL4580743 0.87 KDR (0.50) IKBKBCHUKSCN9AGSK3AGSK3B
SCHEMBL4581040 0.83 KDR (0.51) SMG1KDRSMN1; SMN2CDK2MEN1
SCHEMBL4582327 0.83 HDAC1 (0.47) SCN9AGSK3AGSK3BKDRSMN1; SMN2
SCHEMBL4580829 0.82 HDAC1 (0.42) MEN1LMNAKMT2A
SCHEMBL4581942 0.82 IKBKB (0.46) IKBKBCHUKGSK3BSMG1GRM5
SCHEMBL4580953 0.82 KDR (0.48) GSK3BKDRPTK2IDH1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7323464-B2 Pyridine and pyrimidine derivatives CELLTECH R&D LIMITED (GB) 2008-01-29 US claimed
US-20050080258-A1 Pyridine and pyrimidine derivatives GENTEX CORPORATION 2005-04-14 US claimed
US-7323464-B2 Pyridine and pyrimidine derivatives CELLTECH R&D LIMITED (GB) 2008-01-29 US disclosed
US-20050080258-A1 Pyridine and pyrimidine derivatives GENTEX CORPORATION 2005-04-14 US disclosed
EP-1448555-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES Celltech R & D Limited (GB) 2004-08-25 EP disclosed
WO-2003045941-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080258-A1 Pyridine and pyrimidine derivatives ROR1, MAPK1, IRAK1 IKBKB 130/4885CHUK 28/4885SCN9A 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.